Effect of electrochemotherapy with betulinic acid or cisplatin on regulation of heat shock proteins in metastatic human carcinoma cells in vitro

  • Authors:
    • Justyna Mączyńska
    • Anna Choromańska
    • Justyna Kutkowska
    • Małgorzata Kotulska
    • Maciej Zalewski
    • Jerzy Zalewski
    • Julita Kulbacka
    • Jolanta Saczko
  • View Affiliations

  • Published online on: April 8, 2019     https://doi.org/10.3892/or.2019.7103
  • Pages: 3444-3454
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Betulinic acid (BTA) is naturally occurring triterpene that has received interest as a novel therapeutic substance with cytotoxicity towards a number of cancer cell lines. Despite the wide spectrum of biological and pharmacological effects, its effect may be limited its lipophobic properties. Therefore, strategies to improve the access of BTA to the cells are required to enhance the anticancer effects. Electroporation (EP) enables increased inflow of drugs into cancer cells, even at low doses, which may reduce the side effects caused by high doses of chemotherapy. The potential application of BTA in electrochemotherapy (ECT) in metastatic type of cancers was investigated in the present study. The efficacy of BTA with EP was estimated using a cell survival assay (MTT assay), microscopical morphology analysis and the immunocytochemical expression of heat shock proteins (HSPs). HSPs are molecules that protect the cell from harmful environmental, chemical and physical stresses, and ensure cell survival, recovery and proper functioning. HSP expression is induced various stress factors. Therefore, the expression of HSP27 and HSP70 was evaluated after cells were exposed to an external pulsed electric field and anticancer drugs. Facilitated drug delivery and the anticancer effect on metastatic tumor cells were evaluated in vitro. The effect of BTA was compared with cisplatin (CP), a standard cytostatic agent. Two different metastatic cancer cell lines were used, an ovary adenocarcinoma cell line (SW626) and melanoma cell line (Me45). BTA combined with EP exhibited similar efficacy to CP with EP after 24 and 48 h in SW626 and Me45 cancer cells. Me45 cells also had high HSP27 and low HSP70 immunosignals post‑ECT treatment. ECT caused increased expression of HSP27 and HSP70 proteins in SW626 cells, which were less sensitive to ECT than the Me45 melanoma cell line. The results indicate that BTA may be efficiently applied instead of CP in ECT approaches, but its activity differs between tumor cell lines.

References

1 

Fulda S: Betulinic acid for cancer treatment and prevention. Int J Mol Sci. 9:1096–1107. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Osunsanmi FO, Shode FO and Opoku AR: Anti-inflammatory activity of betulinic acid and its acetyl derivative from melaleuca bracteata. S Afr J Bot. 103:342. 2016.simplehttp://dx.doi.org/10.4314/tjpr.v17i10.13 View Article : Google Scholar

3 

Pavlova NI, Savinova OV, Nikolaeva SN, Boreko EI and Flekhter OB: Antiviral activity of betulin, betulinic and betulonic acids against some enveloped and non-enveloped viruses. Fitoterapia. 74:489–492. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Bringmann G, Saeb W, Assi LA, François G, Sankara Narayanan AS, Peters K and Peters EM: Betulinic acid: Isolation from Triphyophyllum peltatum and Ancistrocladus heyneanus, antimalarial activity, and crystal structure of the benzyl ester. Planta Med. 63:255–257. 1997. View Article : Google Scholar : PubMed/NCBI

5 

Damle AA, Pawar YP and Narkar AA: Anticancer activity of betulinic acid on MCF-7 tumors in nude mice. Indian J Exp Biol. 51:485–491. 2013.PubMed/NCBI

6 

Eiznhamer DA and Xu ZQ: Betulinic acid: A promising anticancer candidate. IDrugs. 7:359–373. 2004.PubMed/NCBI

7 

Rzeski W, Stepulak A, Szymański M, Sifringer M, Kaczor J, Wejksza K, Zdzisińska B and Kandefer-Szerszeń M: Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 374:11–20. 2006. View Article : Google Scholar : PubMed/NCBI

8 

Ehrhardt H, Fulda S, Fuhrer M, Debatin KM and Jeremias I: Betulinic acid-induced apoptosis in leukemia cells. Leukemia. 18:1406–1412. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Schmidt ML, Kuzmanoff KL, Ling-Indeck L and Pezzuto JM: Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer. 33:2007–2010. 1997. View Article : Google Scholar : PubMed/NCBI

10 

Chintharlapalli S, Papineni S, Ramaiah SK and Safe S: Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 67:2816–2823. 2007. View Article : Google Scholar : PubMed/NCBI

11 

Drag-Zalesinska M, Kulbacka J, Saczko J, Wysocka T, Zabel M, Surowiak P and Drag M: Esters of betulin and betulinic acid with amino acids have improved water solubility and are selectively cytotoxic toward cancer cells. Bioorg Med Chem Lett. 19:4814–4817. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD and Brown DM: Discovery of betulinic acid as a selective inhibitor of human-melanoma that functions by induction of apoptosis. Nat Med. 1:1046–1051. 1995. View Article : Google Scholar : PubMed/NCBI

13 

Fulda S and Kroemer G: Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today. 14:885–890. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Cichewicz RH and Kouzi SA: Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev. 24:90–114. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Bache M, Bernhardt S, Passin S, Wichmann H, Hein A, Zschornak M, Kappler M, Taubert H, Paschke R and Vordermark D: Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma-an in vitro study of cytotoxicity and radiosensitization. Int J Mol Sci. 15:19777–19790. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Skolucka N, Saczko J, Kotulska M, Kulbacka J and Choromanska A: Electroporation and its application. Pol Merkur Lekarski. 28:501–504. 2010.(In Polish). PubMed/NCBI

17 

Kotulska M, Kubica K, Koronkiewicz S and Kalinowski S: Modeling the induction of lipid membrane electropermeabilization. Bioelectrochemistry. 70:64–70. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G and Snoj M: Electrochemotherapy in treatment of tumours. Eur J Surg Oncol. 34:232–240. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Kotulska M: Electrochemotherapy in cancer treatment. Adv Clin Exp Med. 16:601–607. 2007.

20 

Kazmierczuk A and Kilianska ZM: The pleiotropic activity of heat-shock proteins. Postepy Hig Med Dosw (Online). 63:502–521. 2009.(In Polish). PubMed/NCBI

21 

Schlesinger MJ: Heat-shock proteins-the search for functions. J Cell Biol. 103:321–325. 1986. View Article : Google Scholar : PubMed/NCBI

22 

Cymerys J and Niemialkowski M: Heat-shock-proteins-molecular-perpetual-motion. Post Biol Kom. 31:332–339. 2004.

23 

Kaigorodova EV and Bogatyuk MV: Heat shock proteins as prognostic markers of cancer. Curr Cancer Drug Targets. 14:713–726. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Kulczynska A, Kostur A and Piszcz J: Heat shock proteins in the pathogenesis and treatment of cancer. Acta Haematol Pol. 41:253–259. 2010.pthit.pl/download,ahp,538.

25 

Kazmierczuk A and Kilianska ZM: Role of heat shock proteins in cell apoptosis. Postepy Hig Med Dosw (Online). 64:273–283. 2010.(In Polish). PubMed/NCBI

26 

Liberek K, Lewandowska A and Zietkiewicz S: Chaperones in control of protein disaggregation. EMBO J. 27:328–335. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Verbeke P, Fonager J, Clark BF and Rattan SI: Heat shock response and ageing: Mechanisms and applications. Cell Biol Int. 25:845–857. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Musial K and Zwolinska D: Heat shock proteins in chronic kidney disease. Pediatr Nephrol. 26:1031–1037. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A and Kroemer G: HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle. 2:579–584. 2003. View Article : Google Scholar : PubMed/NCBI

30 

Calderwood SK: Heat shock proteins and cancer: Intracellular chaperones or extracellular signalling ligands? Philos Trans R Soc Lond B Biol Sci. 373:201605242018. View Article : Google Scholar : PubMed/NCBI

31 

Lee CT and Repasky EA: Opposing roles for heat and heat shock proteins in macrophage functions during inflammation: A function of cell activation state? Front Immunol. 3:1402012. View Article : Google Scholar : PubMed/NCBI

32 

Wang H, Tan MS, Lu RC, Yu JT and Tan L: Heat shock proteins at the crossroads between cancer and Alzheimer's disease. Biomed Res Int. 2014:2391642014.PubMed/NCBI

33 

Vidyasagar A, Wilson NA and Djamali A: Heat shock protein 27 (HSP27): Biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 5:72012. View Article : Google Scholar : PubMed/NCBI

34 

Tian X, Zhao L, Song X, Yan Y, Liu N, Li T, Yan B and Liu B: HSP27 inhibits homocysteine-induced endothelial apoptosis by modulation of ROS production and mitochondrial caspase-dependent apoptotic pathway. Biomed Res Int. 2016:48478742016. View Article : Google Scholar : PubMed/NCBI

35 

Zheng G, Zhang Z, Liu H, Xiong Y, Luo L, Jia X, Peng C, Zhang Q, Li N, Gu Y, et al: HSP27-mediated extracellular and intracellular signaling pathways synergistically confer chemo-resistance in squamous cell carcinoma of tongue. Clin Cancer Res. 24:1163–1175. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Zhang Y and Shen X: Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing akt activation and abating suppression of thioredoxin reductase activity. Clin Canc Res. 13:2855–2864. 2007. View Article : Google Scholar

37 

Wang XP, Wang QX, Lin HP, Xu B, Zhao Q and Chen K: Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity. Oncotarget. 7:71274–71284. 2016.PubMed/NCBI

38 

Shevtsov M and Multhoff G: Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol. 7:1712016. View Article : Google Scholar : PubMed/NCBI

39 

Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, Jarm T, Kos B, Pavliha D, Grcar Kuzmanov B, Cemazar M, et al: Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol. 110:320–327. 2014. View Article : Google Scholar : PubMed/NCBI

40 

Kumala S, Niemiec P, Widel M, Hancock R and Rzeszowska-Wolny J: Apoptosis and clonogenic cell survival in three tumour cell lines exposed to gamma rays or chemical genotoxic agents. Cell Mol Biol Lett. 8:655–665. 2003.PubMed/NCBI

41 

Helm CW and States JC: Enhancing the efficacy of cisplatin in ovarian cancer treatment-could arsenic have a role. J Ovarian Res. 2:22009. View Article : Google Scholar : PubMed/NCBI

42 

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI

43 

Wezgowiec J, Kulbacka J, Saczko J, Rossowska J, Chodaczek G and Kotulska M: Biological effects in photodynamic treatment combined with electropermeabilization in wild and drug resistant breast cancer cells. Bioelectrochemistry. 123:9–18. 2018. View Article : Google Scholar : PubMed/NCBI

44 

Michel O, Kulbacka J, Saczko J, Mączyńska J, Błasiak P, Rossowska J and Rzechonek A: Electroporation with cisplatin against metastatic pancreatic cancer: In vitro study on human primary cell culture. BioMed Res Int. 2018:73645392018. View Article : Google Scholar : PubMed/NCBI

45 

Gothelf A, Mir LM and Gehl J: Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev. 29:371–387. 2003. View Article : Google Scholar : PubMed/NCBI

46 

Saczko J, Kamińska I, Kotulska M, Bar J, Choromańska A, Rembiałkowska N, Bieżuńska-Kusiak K, Rossowska J, Nowakowska D and Kulbacka J: Combination of therapy with 5-fluorouracil and cisplatin with electroporation in human ovarian carcinoma model in vitro. Biomed Pharmacother. 68:573–580. 2014. View Article : Google Scholar : PubMed/NCBI

47 

Esmekaya MA, Kayhan H, Coskun A and Canseven AG: Effects of cisplatin electrochemotherapy on human neuroblastoma cells. J Membr Biol. 249:601–610. 2016. View Article : Google Scholar : PubMed/NCBI

48 

Cemazar M, Sersa G and Miklavcic D: Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin. Anticancer Res. 18:4463–4466. 1998.PubMed/NCBI

49 

Zhao J, Li R, Pawlak A, Henklewska M, Sysak A, Wen L, Yi JE and Obmińska-Mrukowicz B: Antitumor activity of betulinic acid and betulin in canine cancer cell lines. In Vivo. 32:1081–1088. 2018. View Article : Google Scholar : PubMed/NCBI

50 

Xu J, Wang X, Zhang H, Yue J, Sun Y, Zhang X and Zhao Y: Synthesis of triterpenoid derivatives and their anti-tumor and anti-hepatic fibrosis activities. Nat Prod Res. 16:1–7. 2018. View Article : Google Scholar

51 

Chintharlapalli S, Papineni S, Lei P, Pathi S and Safe S: Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer. 11:3712011. View Article : Google Scholar : PubMed/NCBI

52 

Sun L, Cao J, Chen K, Cheng L, Zhou C, Yan B, Qian W, Li J, Duan W, Ma J, et al: Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Int J Oncol. 54:98–110. 2019.PubMed/NCBI

53 

Periasamy G, Teketelew G, Gebrelibanos M, Sintayehu B, Gebrehiwot M, Karim A and Geremedhin G: Betulinic acid and its derivatives as anti-cancer agent: A review. Arch Appl Sci Res. 6:47–58. 2014.

54 

Yang S, Liang N, Li H, Xue W, Hu D, Jin L, Zhao Q and Yang S: Design, synthesis and biological evaluation of novel betulinic acid derivatives. Chem Cent J. 6:1412012. View Article : Google Scholar : PubMed/NCBI

55 

Pandita A, Kumar B, Manvati S, Vaishnavi S, Singh SK and Bamezai RN: Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression. PLoS One. 9:e1071542014. View Article : Google Scholar : PubMed/NCBI

56 

Kutkowska J, Strzadala L and Rapak A: Sorafenib in combination with betulinic acid synergistically induces cell cycle arrest and inhibits clonogenic activity in pancreatic ductal adenocarcinoma cells. Int J Mol Sci. 19:E32342018. View Article : Google Scholar : PubMed/NCBI

57 

Mlakar V, Todorovic V, Cemazar M, Glavac D and Sersa G: Electric pulses used in electrochemotherapy and electrogene therapy do not significantly change the expression profile of genes involved in the development of cancer in malignant melanoma cells. BMC Cancer. 9:2992009. View Article : Google Scholar : PubMed/NCBI

58 

Dressel R, Baraki H, Langer F and Gunther E: Reduced susceptibility of electroporated tumor cell lines to killing by cytotoxic lymphocytes. Biochem Biophys Res Commun. 250:259–263. 1998. View Article : Google Scholar : PubMed/NCBI

59 

Vargas-Roig LM, Gago FE, Tello O, Aznar JC and Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer. 79:468–475. 1998. View Article : Google Scholar : PubMed/NCBI

60 

Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH and Van der Zee AG: Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: Relation in response to chemotherapy and prognosis. Int J Cancer. 84:234–238. 1999. View Article : Google Scholar : PubMed/NCBI

61 

Tóth ME, Gombos I and Sántha M: Heat shock proteins and their role in human diseases. Acta Biol Szeged. 59:121–141. 2015.simplehttps://www2.sci.u-szeged.hu/ABS/2015/Acta%20HPb/59121.pdf

62 

Talele S and Gaynor P: Non-linear time domain model of electropermeabilization: Effect of extracellular conductivity and applied electric field parameters. J Electrost. 66:328–334. 2008.simplehttps://doi.org/10.1016/j.elstat.2008.02.002 View Article : Google Scholar

63 

Hui TH, Zhou ZL, Fong HW, Ngan RK, Lee TY, Au JS, Ngan AH, Yip TT and Lin Y: Characterizing the malignancy and drug resistance of cancer cells from their membrane resealing response. Sci Rep. 6:266922016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mączyńska, J., Choromańska, A., Kutkowska, J., Kotulska, M., Zalewski, M., Zalewski, J. ... Saczko, J. (2019). Effect of electrochemotherapy with betulinic acid or cisplatin on regulation of heat shock proteins in metastatic human carcinoma cells in vitro. Oncology Reports, 41, 3444-3454. https://doi.org/10.3892/or.2019.7103
MLA
Mączyńska, J., Choromańska, A., Kutkowska, J., Kotulska, M., Zalewski, M., Zalewski, J., Kulbacka, J., Saczko, J."Effect of electrochemotherapy with betulinic acid or cisplatin on regulation of heat shock proteins in metastatic human carcinoma cells in vitro". Oncology Reports 41.6 (2019): 3444-3454.
Chicago
Mączyńska, J., Choromańska, A., Kutkowska, J., Kotulska, M., Zalewski, M., Zalewski, J., Kulbacka, J., Saczko, J."Effect of electrochemotherapy with betulinic acid or cisplatin on regulation of heat shock proteins in metastatic human carcinoma cells in vitro". Oncology Reports 41, no. 6 (2019): 3444-3454. https://doi.org/10.3892/or.2019.7103